Research programme: transdermal amfetamine patch - Noven/Shire
Latest Information Update: 20 Feb 2008
At a glance
- Originator Noven Pharmaceuticals
- Mechanism of Action Adrenergic receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder
Most Recent Events
- 09 Aug 2006 Preclinical trials in Attention-deficit hyperactivity disorder in USA (Transdermal)